(Updated on January 01, 2023)
Information of Publisher
American Journal of Translational Medicine (ISSN 2474 -7378 for print, ISSN 2474-7386 for online) is a peer-reviewed biomedical journal published by Hawaii Gangze Inc in Honolulu, Hawaii, USA, since 2017.
The Publisher's website is below:
The Journal's webpage link is below:
Aims & scope
American Journal of Translational Medicine (ISSN 2474 -7378 for print, ISSN 2474-7386 for online) is a peer-reviewed international biomedical journal publishing articles focusing on information derived from human experimentation so as to optimize the communication between basic and clinical science.
The journal covers all areas of translational medicine but also has several special sections:
- Artificial Intelligence (AI) and health
- Cancer microenvironment
- Cardiovascular, Metabolic, and Lipoprotein Translation
- Cell, Tissue, and Gene therapy
- Child health
- Clinical Translation
- Disease biomarkers
- Infectious diseases including COVID-19
- Immunobiology and Immunotherapy
- Medical Bioinformatics
- Nutrition and metabolism
- Patient-targeted molecular therapies
- Reproduction and health
- Stem cell therapy
- Tissue engineering and regenerative medicine
Currently, the journal will not provide Open access service, but it may be available for part of an article in 2023 or later. This journal will go to the style of a Hybrid open access journal from 2023. A hybrid open-access journal is a subscription journal in which some of the articles are open-access. This status typically requires the payment of a publication fee (also called an article processing charge (APC) or open-assessing fee (OA fee) to the publisher.
American Journal of Translational Medicine may charge $50 as an Article-processing fee at this stage (2023)
American Journal of Translational Medicine charges a publication fee of $800 per article in 2023 on black and white pages. The color figure (page) is charged an additional $150 per figure (page).
The bibliographic databases that index articles published in the American Journal of Translational Medicine include:
- Google Scholar
- International Scientific Indexing (ISI)
Publication and peer review process
The peer review process has these types: open, or single-blind, AJTM journal takes the single-blind type. The peer-review process normally will take 3 or 4 weeks after submission
The manuscripts will be reviewed by two experts in a similar field. If two reviewers’ recommendation about acceptance is controversial, the editor-in-chief will ask a third reviewer to read the manuscript and offer a recommendation and make decisions about acceptance.
After review, the paper can be asked for a major revision or minor revision exempt from direct acceptance.
High-quality, bound reprints can be purchased for all articles published. They can be ordered after the manuscript has been accepted for publication
American Journal of Translational Medicine will consider supplements based on proceedings (full articles or meeting abstracts), reviews, or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online on the journal website and can also be produced in print. For further information, please contact us by email at email@example.com
All manuscripts submitted to the American Journal of Translational Medicine should adhere to Hawaii Gangze Inc., the Publisher's editorial policies. The link is as follows:
Why publish your article in the American Journal of Translational Medicine?
- High visibility
American Journal of Translational Medicine's publishing policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a " highly assessed" graphic, which appears on the journal's contents pages and searches results.
- Speed of publication
American Journal of Translational Medicine offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through the American Journal of Translational Medicine.
Online publication in the American Journal of Translational Medicine gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves and to create all relevant links (to sequence and other databases, and to other articles).
- Promotion and press coverage
Articles published in the American Journal of Translational Medicine are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on the American Journal of Translational Medicine's pages and on the Hawaii Gangze Inc., Publisher homepage.
In addition, articles published in the American Journal of Translational Medicine may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of access to articles published in the American Journal of Translational Medicine.
- Plagiarism Policy
Plagiarism is the unethical act of copying someone else’s prior ideas, processes, results, or words without explicit acknowledgment of the original author and source. Self-plagiarism occurs when an author utilizes a large part of his/her own previously published work without using appropriate references. This can range from getting the same manuscript published in multiple journals to modifying a previously published manuscript with some new data.
In no case shall a journal and members of the editorial board and international scientific committee encourage misconduct of any kind or knowingly allow such misconduct to take place. Members of the editorial board and the international scientific committee shall try to prevent misconduct by informing authors and reviewers about the ethical conduct required of them. Members of the editorial board, scientific committee, and reviewers are asked to be aware of all types of misconduct in order to identify papers where research misconduct of any kind has or seems to have occurred and deal with the allegations accordingly.
All manuscripts submitted for publication to the journal are cross-checked for plagiarism using Turnitin software. Manuscripts found to be plagiarized during the initial stages of review are out-rightly rejected and not considered for publication in the journal. In case a manuscript is found to be plagiarized after publication, the Editorial Board will conduct a preliminary investigation, maybe with the help of a suitable committee constituted for the purpose. A determination of misconduct will lead the journal to run a statement bi-directional linked online to and from the original paper, to note the plagiarism and provide a reference to the plagiarized material. The paper containing the plagiarism will also be marked on each page of the PDF. Upon determination of the extent of plagiarism, the paper may also be formally retracted.
Policy and Action for Plagiarism:
Journal respects intellectual property and aims at protecting and promoting the original work of its authors. Manuscripts containing plagiarized material are against the standards of quality, research, and innovation. Hence, all authors submitting articles to journals are expected to abide by ethical standards and abstain from plagiarism, in any form. In case, an author is found to be suspected of plagiarism in a submitted or published manuscript then, the journal shall contact the author (s) to submit his / her (their) explanation within two weeks, which may be forwarded to the Fact-Finding Committee (FFC) constituted for the purpose, for further course of action.
Upon having established that the manuscript is plagiarized from some previously published work, Journal shall support the original author and manuscript irrespective of the publisher and may take any or all of the following immediate actions or follow the additional course of actions as recommended by the committee:
- Journal shall remove the PDF copy of the published manuscript from the website and disable all links to the full-text article. The term Plagiarized Manuscript shall be appended to the published manuscript title.
- Journal shall disable the author’s account with the journal and reject all future submissions from the author for a period of 03 / 05 / 10 years or even ban the authors permanently.
- Journal may also display the list of such authors along with their full contact details on the journal website.
- Any other course of action, as recommended by the Committee or as deemed fit for the instant case or as decided by the editorial board from time to time.
Authors of articles published in the American Journal of Translational Medicine need to transfer the copyright of their articles to Hawaii Gangze Inc, Publisher (for further details, see the Hawaii Gangze Inc., Publisher Copyright and License Agreement
The Journal's revenue sources include: page charges, subscriptions, adverting, and reprints
It is important that every author of a contribution be credited as such. It is equally as important that a person not be named as an author when he or she is not.
- Hawaii Gangze Inc’s preference is for authors to resolve such matters amongst themselves, although that is not always possible.
- The complainant must be made aware that the matter cannot be investigated unless the journal editor informs the corresponding author or author about whom a complaint has been made (as a matter of “due process”) and possibly the institution or company at which the research took place (the complainant may not wish to make the complaint at such a formal level).
- In that communication, the editor should indicate that the matter may be referred to the institution or company where the research took place or any other relevant institution or agency (for example a funding agency) unless the author provides a reasonable explanation (accepted as reasonable by the editor). NOTE: some agencies such as the NIH’s Office of Research Integrity (https://ori.hhs.gov), will not consider disputes that are solely about authorship.
- It may be advisable for the editor in this fact-finding process to request the views and comments of third parties who may be expected to have knowledge of the facts alleged by the complainant.
Chair(Director): Dr. Xi-Dai Long
Members: Dr.Mudassor Iqbal, Dr. Yan Lei, Dr. Yomgchang Qin
Website of Journal
Manuscript submission: https://ajtm.journals.publicknowledgeproject.org/index.php/ajtm/about/submissions